

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)



(10) International Publication Number
WO 2023/059671 A1

(51) International Patent Classification:

A61M 5/20 (2006.01) A61M 5/32 (2006.01)
A61M 5/315 (2006.01) A61M 5/24 (2006.01)

(US). SONDERBY, Thomas, Peter; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(21) International Application Number:

PCT/US2022/045716

(74) Agent: FURMANEK, Michael, P.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(22) International Filing Date:

05 October 2022 (05.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/252,940 06 October 2021 (06.10.2021) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: SPORK, Emil, Gram; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). MELANDER, Matias; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). GEGELASHVILI, Alexandre; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). SONG, Yangkun; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: IMPACT ACTIVATED RETENTION FEATURE FOR DRUG DELIVERY DEVICE




FIG. 1

(57) Abstract: A drug delivery device includes a housing having proximal and distal ends and a longitudinal axis extending therebetween, an injection assembly at least partially disposed within the housing including a needle or a cannula, a drive assembly operably coupled with the injection assembly, a shield slidably coupled with the housing and operably coupled with the drive assembly, and a retention mechanism. The drive assembly is engageable to deliver a medicament via the injection assembly. The shield is positionable in an extended position in which at least a proximal end extends a distance beyond the proximal end of the housing and a retracted position where the proximal end of the housing protrudes a distance beyond the proximal end of the shield. Moving the shield to the retracted position engages the drive assembly to deliver the medicament via the injection assembly. The retention mechanism limits movement of the drive assembly to restrict engagement thereof such that the drive assembly is restricted from delivering the medicament via the injection assembly.

WO 2023/059671 A1

[Continued on next page]

MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*